MRCKβ

MRCKβ (myotonic dystrophy kinase-related Cdc42-binding kinase β), encoded by CDC42BPB, is a serine/threonine kinase that functions as a downstream effector of the Rho GTPase Cdc42 and regulates actomyosin cytoskeletal organization, cell polarity, and migration through phosphorylation of substrates involved in myosin contractility^[1][2]. Mechanistically, MRCKβ promotes myosin light chain (MLC) phosphorylation and cooperates with additional cytoskeletal regulators to control actin-myosin dynamics required for cell shape remodeling and directional movement^[2][3]. MRCKβ shares substantial kinase-domain homology with MRCKα and partially overlapping substrate specificity with ROCK kinases; however, its C-terminal regulatory architecture differs from ROCK family members, supporting distinct signaling functions during cytoskeletal regulation and invasion^[2]. In cancer models, Cdc42-MRCK signaling contributes to mesenchymal cell invasion, collective migration, and extracellular matrix penetration by sustaining actomyosin contractility, and combined inhibition of MRCK and ROCK produces stronger suppression of invasive behavior than targeting either pathway alone^[2][4]. MRCKβ has therefore emerged as a relevant experimental target in tumor invasion studies, particularly in breast cancer and squamous cell carcinoma models^[2][4]. For research applications, selective MRCK inhibitors including BDP-9066, BDP8900, and related small molecules suppress substrate phosphorylation, cell migration, and invasion, providing useful pharmacological tools for dissecting MRCK-dependent signaling networks and evaluating anti-invasive therapeutic strategies^[4][5][6].